Coherus appoints Jill O'Donnell-Tormey, Ph.D. to board effective May 18, 2022

Coherus Oncology, Inc.

Board expanded from 7 to 8 directors; O'Donnell-Tormey appointed as Class II director, term through 2025 annual meeting.
She is CEO of Cancer Research Institute since 1993; also serves on boards of CUNY, Richmond University Medical Center.
Will receive $50,000 annual cash retainer and option for 54,000 shares vesting over three years.
Appointed to the Nominating Committee of the Board.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Jill O'Donnell-Tormey

Director

CHRS · Coherus Oncology, Inc.

Effective: 2022-05-18
Filed: May 13, 2022, 7:59 PM ET

the Board of Directors (the “Board”) of Coherus BioSciences, Inc. (the “Company”) increased the authorized number of directors that can serve on the Board from seven to eight directors and, upon the recommendation of its Nominating and Corporate Governance Committee (the “Nominating Committee”), resolved that the vacancy on the Board created by such increase would be filled with the appointment of Jill O’Donnell-Tormey, Ph.D. effective May 18, 2022.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 1.0

Jill O'Donnell-Tormey was appointed as Director at Coherus Oncology, Inc..

Action: appointed
Role: Director

Exact text from the filing

the Board of Directors (the “Board”) of Coherus BioSciences, Inc. (the “Company”) increased the authorized number of directors that can serve on the Board from seven to eight directors and, upon the recommendation of its Nominating and Corporate Governance Committee (the “Nominating Committee”), resolved that the vacancy on the Board created by such increase would be filled with the appointment of Jill O’Donnell-Tormey, Ph.D. effective May 18, 2022.

View on SEC.gov

Coherus Oncology, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-22-150187

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.